Want to join the conversation?
$PFE said the Phase 3 INO-VATE ALL study results showed improvement over chemotherapy on various measures including complete hematologic remission and progression-free survival. This is an open-label, randomized study evaluating safety and efficacy of inotuzumab ozogamicin in adults with relapsed CD22-positive acute lymphoblastic leukemia.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)